Related posts
Top Stocks with Groundbreaking Potential in the DNS Manipulation and Gene-Editing MarketsThis summary was created by AI, based on 7 opinions in the last 12 months.
Based on the reviews from different experts, United Therapeutics Corp (UTHR-Q) is a top pick that is progressing well. The company has achieved all-time high revenues and continues to grow its cash reserves and reduce debt. The maker of pulmonary hypertension medications is well diversified among multiple products, allowing margins to continue to grow. The stock trades at reasonable valuations and has upside potential with a recommended stop-loss in place.
United Therapeutic (UTHR-Q) or Allergan (AGN-N)? This is a tough one because they are 2 very different companies. Allergan is a much larger company and more broadly-based, however, this one is a very fine company. Its primary drug therapy is dealing with pulmonary disease. The risk of owning this is that one drug represents a high percentage of their total revenue.
A good company. ROC has been improving, and has been very high. Back in 2008, it had a 4% ROC. Including the trailing 4 quarters, he now shows a 35% ROC, so he knows the company is doing everything right. Remember that when you have that high return, it can turn over really fast, but for now it is good.
(A Top Pick Dec 19/12. Up 115.38%.) Involved in a very specialized area, pulmonary arterial hypertension, which is high blood pressure in the lungs. The big spike in the stock price came as a result of FDA approval of an oral application for one of their drugs. They are quickly establishing themselves as the “go to” drug maker in this critical area where a lot of people are at risk.
(A Top Pick Dec 19/12. Up 81.38%.) Bio-pharmas are interesting because they have got a pipeline that is very exciting with new drugs coming on that are biology-based as opposed to chemical-based. Have always been extremely expensive, but this one isn’t. Trading at about 14-15 times next years earnings. There has to be a continuation of the acceptance of the existing product, but what he is really hoping for is an expansion of their product offering. They have 3 main drugs that they get most of their revenues off of. He’d like to see that at 6 or 12.
It is going to be news driven. In October one of their drugs was turned down by the FDA. The more drugs they have in their pipeline the less you will see of this. Growing well. Thinks it is good value. 10 times earnings.
United Therapeutics Corp. is a American stock, trading under the symbol UTHR-Q on the NASDAQ (UTHR). It is usually referred to as NASDAQ:UTHR or UTHR-Q
In the last year, 5 stock analysts published opinions about UTHR-Q. 5 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for United Therapeutics Corp..
United Therapeutics Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for United Therapeutics Corp..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
5 stock analysts on Stockchase covered United Therapeutics Corp. In the last year. It is a trending stock that is worth watching.
On 2024-12-05, United Therapeutics Corp. (UTHR-Q) stock closed at a price of $374.03.
Our PAST TOP PICK with UTHR is progressing well. To remain disciplined, we recommend trailing up the stop (from $317) to $349 at this time.